Another research developed two glypican-3 (GPC3)-specific CAR-NK-92 cell lines (GPC3-CAR-NK), and observed that the administration of GPC3-CAR-NK cells may represent a potential therapeutic strategy for HCC. The gene discussed is GPC3; the disease is hepatocellular carcinoma.